Healthy toddlers aged 12 to 23 months will be enrolled and randomized depending on the meningococcal background to receive either MenACYW conjugate vaccine or Nimenrix®. They will be assessed for immunogenicity assessment at baseline (pre-vaccination) and post-vaccination. Safety information will be collected post-vaccination and through the entire study.